 |
|
|
| |
Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study
|
| |
| |
20th European AIDS Conference; October 15-18, 2025; Paris, France
Margaret Gartland,1 Peter Leone,1 Fangfang Du,2 David Dorey,3 Kathryn Brown,4 Thijs Zweers,4 Yash Gandhi,2 Paul Wannamaker,1 Rulan Griesel,5 Chelsea Macfarlane,1 Viviana Wilches,2 Babafemi Taiwo,1 Sherene Min,1 Jan Losos1
1ViiV Healthcare, Durham, NC, USA; 2GSK, Collegeville, PA, USA; 3GSK, Mississauga, Ontario, Canada; 4Certara, Radnor, PA, USA; 5ViiV Healthcare, London, UK
|
| |
|
|
|
|
|
